Contact
searchSearch
HMP Global
Login

Bladder Cancer

Videos
Detecting Molecular Relapse After Immunotherapy in Urothelial Carcinoma and Renal Cell Carcinoma Using ctDNA
06/05/2025
Lingbin Meng, MD, PhD
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could...
06/05/2025
Journal of Clinical Pathways
FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Stephanie Holland
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
From Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
Allison Casey
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
From Oncology
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
Grace Taylor, MS, MA
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Therapy Guidelines in Bladder Cancer
08/26/2022
Yvette C. Terrie, BS Pharm, RPh
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for...
08/26/2022
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022
Ellen Kurek
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
Research Reports
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
05/18/2021
Drishti Shah, PhD; Jason Yeaw, MPH; Amy Kincaid, MA; Paul N. Mudd, Jr., PharmD, MBA; Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and...
05/18/2021
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/24/2021
Janelle Bradley
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical...
03/24/2021
Journal of Clinical Pathways
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/10/2021
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National...
03/10/2021
Journal of Clinical Pathways

Expert Insights

Videos
Detecting Molecular Relapse After Immunotherapy in Urothelial Carcinoma and Renal Cell Carcinoma Using ctDNA
06/05/2025
Lingbin Meng, MD, PhD
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could revolutionize post-immunotherapy surveillance by detecting cancer relapse weeks before traditional imaging.
Discover how ctDNA testing could...
06/05/2025
Journal of Clinical Pathways
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023
David Bogumil
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways
Videos
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
02/18/2021
02/18/2021
Journal of Clinical Pathways
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical Summary Dual-targeting CAR T-cell therapy shows promise: Findings from the phase 2 ZUMA-14 trial suggest that combining axicabtagene ciloleucel (axi-cel) with rituximab may improve response durability by...
  Key Clinical...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Interview
Cardiopulmonary Comorbidities and CRS Risk After CAR T-Cell Therapy in DLBCL: Insights From Real-World Data
06/11/2026
Heidi Cho, MD
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that...
06/11/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis: Part 2
05/27/2026
Nishanth Thalambedu, MD
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the ongoing barriers to CAR T access and the strategies needed to expand equitable treatment for patients with diffuse large B-cell lymphoma (DLBCL).
This discussion explores the...
05/27/2026
Journal of Clinical Pathways
Diffuse Large B-Cell Lymphoma, DLBCL
Videos
Real-World Survival Impact of CAR T Therapy in Advanced DLBCL: Findings From a SEER Database Analysis
05/26/2026
Nishanth Thalambedu, MD
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis demonstrates significant improvements in overall survival for patients with diffuse large B-cell lymphoma (DLBCL) following the introduction of CAR T therapy.
A SEER database analysis...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part II
05/26/2026
Mark A. Socinski, MD
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of this interview, a guest expert reflects on the broader implications of the negative SKYSCRAPER-06 results for the future of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory...
In the second installment of...
05/26/2026
Journal of Clinical Pathways
Mark A. Socinski, MD
Interview
The Ongoing Challenges Facing TIGIT Inhibitors in Lung Cancer: Part I
05/21/2026
Mark A. Socinski, MD
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this interview, a guest expert discusses the phase 3 SKYSCRAPER-06 trial evaluating tiragolumab plus atezolizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. He reviews the study...
In the first part of this...
05/21/2026
Journal of Clinical Pathways

Newsfeed

FDA Approval
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024
Stephanie Holland
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
Allison Casey
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023
Grace Taylor, MS, MA
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022
Ellen Kurek
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
News
JAK Inhibitors Demonstrate Improved Efficacy but Worse Toxicity in Myelofibrosis
07/13/2026
Rebecca Amrick
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase (JAK) inhibitors demonstrate increased effectiveness but also higher toxicity than traditional therapies for myelofibrosis, illustrating the balance between halting disease progression and maintaining quality...
A study found that Janus kinase...
07/13/2026
Journal of Clinical Pathways
News
Circulating Tumor DNA Could Improve Minimal Residual Disease Detection for Ovarian Cancer
06/26/2026
Rebecca Amrick
Circulating tumor DNA shows promise as a non-invasive alternative to second look laparoscopy at detecting minimal residual disease detection and predicting survival outcomes for patients with ovarian cancer.
Circulating tumor DNA shows promise as a non-invasive alternative to second look laparoscopy at detecting minimal residual disease detection and predicting survival outcomes for patients with ovarian cancer.
Circulating tumor DNA shows...
06/26/2026
Journal of Clinical Pathways
News
IOTA ADNEX Model Outperforms Current Ovarian Cancer Triage Standard
06/23/2026
Hannah Musick
The International Ovarian Tumour Analysis Assessment of Different Neoplasias (IOTA ADNEX) ultrasound model more than doubled ovarian cancer detection sensitivity compared with the current Risk of Malignancy Index standard, supporting its...
The International Ovarian Tumour Analysis Assessment of Different Neoplasias (IOTA ADNEX) ultrasound model more than doubled ovarian cancer detection sensitivity compared with the current Risk of Malignancy Index standard, supporting its...
The International Ovarian Tumour...
06/23/2026
Journal of Clinical Pathways
News
CAR T Therapy Demonstrates Improved Efficacy but Increased Toxicity in Patients With Relapsed or Refractory MM
06/22/2026
Rebecca Amrick
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR) T-cell therapy demonstrates better efficacy than teclistamab in treating relapsed of refractory multiple myeloma (MM), but higher rates of adverse events could complicate decision-making for physicians and...
Chimeric antigen receptor (CAR)...
06/22/2026
Journal of Clinical Pathways
News
Frailty Predicts Fewer Days at Home After Ovarian Cancer Surgery
06/17/2026
Hannah Musick
Frailty—not age alone—was the strongest predictor of reduced time spent alive and at home during the year after ovarian cancer surgery, with frail older adults experiencing substantially worse long-term recovery and higher mortality than...
Frailty—not age alone—was the strongest predictor of reduced time spent alive and at home during the year after ovarian cancer surgery, with frail older adults experiencing substantially worse long-term recovery and higher mortality than...
Frailty—not age alone—was the...
06/17/2026
Journal of Clinical Pathways
News
HCC Surveillance Rates Declined During COVID-19 and Remain Low in the Post-Pandemic Era
06/16/2026
Rebecca Amrick
Hepatocellular carcinoma (HCC) surveillance decreased during the COVID-19 pandemic, and rates have not yet rebounded to pre-pandemic levels, sparking concern among researchers and calling for a need to expand care access and implement...
Hepatocellular carcinoma (HCC) surveillance decreased during the COVID-19 pandemic, and rates have not yet rebounded to pre-pandemic levels, sparking concern among researchers and calling for a need to expand care access and implement...
Hepatocellular carcinoma (HCC)...
06/16/2026
Journal of Clinical Pathways
News
High-Volume Facilities Are Linked to Improved Survival Outcomes for Patients With MM
06/09/2026
Rebecca Amrick
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are associated with improved outcomes for patients with multiple myeloma (MM), indicating the role physician experience and facility recognition might play in treatment.
High-volume facilities are...
06/09/2026
Journal of Clinical Pathways
News
Telemedicine Expansion Not Associated With Higher Health Care Utilization or Costs
06/08/2026
Rebecca Amrick
Analyzing data from MedInsight, researchers found no significant association between telemedicine adoption and care utilization and spending, alleviating worries about the impact of telemedicine expansion on the US health care system.
Analyzing data from MedInsight, researchers found no significant association between telemedicine adoption and care utilization and spending, alleviating worries about the impact of telemedicine expansion on the US health care system.
Analyzing data from MedInsight,...
06/08/2026
Journal of Clinical Pathways
News
Geographic Distribution Creates Disparities in Access to MM CAR T Care Centers
06/03/2026
Rebecca Amrick
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of multiple myeloma (MM) chimeric antigen receptor (CAR) T care centers in the US illustrated how uneven distribution of these centers contributes to inequitable access, especially for socially vulnerable and underserved...
A geospatial analysis of...
06/03/2026
Journal of Clinical Pathways
News
Bispecific Antibodies Demonstrate Favorable Real-World Outcomes for R/R Follicular Lymphoma
05/29/2026
Rebecca Amrick
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies demonstrate high efficacy rates and low safety risks when used to treat relapsed or refractory (R/R) follicular lymphoma in real-world settings, indicating their ability to improve patient outcomes.
Bispecific antibodies...
05/29/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use